Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy?
Crossref DOI link: https://doi.org/10.1007/s40618-017-0717-8
Published Online: 2017-06-20
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Piantanida, E.
Bartalena, L.
License valid from 2017-06-20